open access

Vol 29, No 1 (2022)
Research Letter
Submitted: 2021-05-06
Accepted: 2021-10-13
Published online: 2021-12-17
Get Citation

Does canagliflozin decrease natriuretic peptide levels in patients with diabetes and heart failure?

Ernesto Martín12, Juan C. Castillo12, Rafael González-Manzanares12, José López Aguilera12, Jorge Perea12, Manuel Anguita12
DOI: 10.5603/CJ.a2021.0169
·
Pubmed: 34931694
·
Cardiol J 2022;29(1):166-169.
Affiliations
  1. Department of Cardiology, Hospital Universitario Reina Sofía, Córdoba, Spain
  2. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Universidad de Córdoba, Córdoba, Spain

open access

Vol 29, No 1 (2022)
Research letters — Clinical cardiology
Submitted: 2021-05-06
Accepted: 2021-10-13
Published online: 2021-12-17

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Does canagliflozin decrease natriuretic peptide levels in patients with diabetes and heart failure?

Journal

Cardiology Journal

Issue

Vol 29, No 1 (2022)

Article type

Research Letter

Pages

166-169

Published online

2021-12-17

Page views

2625

Article views/downloads

421

DOI

10.5603/CJ.a2021.0169

Pubmed

34931694

Bibliographic record

Cardiol J 2022;29(1):166-169.

Authors

Ernesto Martín
Juan C. Castillo
Rafael González-Manzanares
José López Aguilera
Jorge Perea
Manuel Anguita

References (9)
  1. Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Eng J Med. 2015; 373(22): 2117–2128.
  2. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377(7): 644–657.
  3. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347–357.
  4. McMurray JJV, Solomon SD, Inzucchi SE. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Eng J Med. 2019; 381(20): 1995–2008.
  5. Packer M, Anker SD, Butler J, et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017; 2(9): 1025–1029.
  6. Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019; 140(18): 1463–1476.
  7. Januzzi JL, Butler J, Jarolim P, et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017; 70(6): 704–712.
  8. Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020; 22(4): 713–722.
  9. Garg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis. 2019; 62(4): 349–357.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl